GH Research (NASDAQ:GHRS) Receives “Buy” Rating from HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $40.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 321.05% from the company’s previous close. HC Wainwright also issued estimates for GH Research’s FY2029 earnings at $0.10 EPS.

Separately, Canaccord Genuity Group dropped their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th.

GH Research Stock Up 7.8 %

Shares of GHRS stock opened at $9.50 on Monday. The stock has a market cap of $494.29 million, a PE ratio of -12.03 and a beta of 0.84. GH Research has a 52-week low of $6.00 and a 52-week high of $14.99. The business has a 50-day simple moving average of $8.41 and a 200-day simple moving average of $8.92.

Hedge Funds Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. grew its holdings in GH Research PLC (NASDAQ:GHRS) by 1.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 6,686,689 shares of the company’s stock after acquiring an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).